Acquired Immune Deficiency Syndrome (AIDS) Antiretroviral Therapy


Article Author:
Andres Mora Carpio


Article Editor:
Abdullah Adil


Editors In Chief:
David Wood
Andrew Wilt
Mary Cataletto


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
6/3/2019 3:09:00 PM

Introduction

Human immunodeficiency virus (HIV) infection has become a health problem worldwide. Advances in treatment have made this disease not only manageable but have also dramatically decreased the incidence of opportunistic infections and decreased progression to acquired immunodeficiency syndrome (AIDS). Current guidelines on HIV treatment are more aggressive on when to start treatment, given that recent studies have shown improved outcomes with earlier initiation of therapy. In this review, we will focus on HIV antiretroviral therapy.[1][2]

Etiology

HIV is an enveloped ribonucleic retrovirus, subgroup lentivirus. There are two species of HIV that cause human disease. HIV-1 has high virulence and infectivity and is prevalent worldwide, HIV-2 has lower virulence and infectivity and is more prevalent in West Africa.

Epidemiology

HIV prevalence has increased worldwide. This is related to an increased survival of HIV-infected individuals thanks to highly active antiretroviral therapy. The incidence of HIV has been declining and is expected to keep declining with increased awareness of the disease and the advent of pre-exposure prophylaxis therapy.

Pathophysiology

HIV transmission occurs through the exchange of bodily fluids. The most common route of transmission is sexual through the anogenital mucosa. It penetrates into the body by binding its GP120 molecule to CD4 molecules on dendritic cells in the mucosa. After entering the body, the virus invades macrophages (by binding GP120 to the chemokine receptor CCR5 as well as CD4) or T cell (by binding GP120 to the chemokine receptor CXCR4 as well as CD4) depending on the virus. After penetrating the cell, viral RNA will get transcribed to DNA by the virus own Reverse transcriptase. The DNA is then included into the host's DNA with the use of the virus Integrase enzyme. This DNA later transcribes into new RNA molecules that will be enveloped by proteins that have been cleaved into form by the HIV protease. These forms mature virions that later bud out of the cell and go to infect other cells. Highlighted in bold are those places where HIV antiretroviral therapy acts on different parts of the viral cycle.[3]

History and Physical

Acute HIV infection may manifest as a mononucleosis-like syndrome with mainly nonspecific symptoms or be completely asymptomatic.

Chronic untreated infection progresses to CD-4 cell depletion and the development of acquired immunodeficiency syndrome with the appearance of different opportunistic infections and metabolic, cardiovascular, oncologic and neurocognitive comorbidities.

Evaluation

New more sensitive tests for HIV detection have been developed, and the diagnostic algorithm has been recently revised and updated. Initial diagnostic testing and screening should be done with antigen/antibody (4th gen) immunoassay that detects both HIV-1 and 2, as well as p24 antigen. This allows for earlier detection of infection by adding direct antigen testing to the initial screen (3rd generation immunoassays tested only for antibodies). A negative specimen does not require further testing. Patients with a positive test should be confirmed with an antibody immunoassay that differentiates HIV-1 from HIV-2 (as opposed to western blot). Positive tests define the diagnosis of HIV and subspecies. Patients that have a negative result or indeterminate in a confirmatory test should be tested with an HIV-1 NAT (nucleic acid testing). A positive test indicates acute HIV-1 infection. A negative test indicates a false positive result in initial testing and patient should be considered not infected. After confirmation of diagnosis and before initiation of treatment all patients should have a CD4 cell count, HIV RNA viral load, complete metabolic and blood count done, as well as genotypic resistance testing for the virus.[4]

Treatment / Management

There are many different categories of HIV antiretroviral therapy:

  • Medications that prevent entry of the virus into the cell by inhibiting CCR5 or GP41 are called fusion or entry inhibitors.
  • Medications that prevent transcription of viral RNA into DNA are called nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI).
  • Medication that inhibits the integration of transcribed viral DNA into the host's DNA is called integrase inhibitors.
  • Finally, medications that prevent protein cleavage from forming a virion are called protease inhibitors.

Who and How to treat?

Based on recent multicenter-multinational randomized controlled trials the latest guidelines indicate that HIV antiretroviral therapy should be initiated early in the disease process regardless of CD4 cell count in all adult and adolescent patients. This strategy has been shown to decrease morbidity and mortality related to HIV infection as well as HIV transmission.[5][6]

HIV antiretroviral therapy should always be done with combination regimens. Initial treatment usually consists of two NRTIs (usually abacavir/lamivudine or tenofovir/emtricitabine) in combination with a third antiviral drug from one of the following classes: integrase inhibitor, NNRTI or protease inhibitor plus an enhancer (cobicistat or ritonavir). This is based on the proven efficacy of this regimen and more favorable side effect profile. Alternative treatments may be considered in special patients.

Recommended initial regimens include four integrase inhibitor-based regimens (Dolutegravir/Tenofovir Fumarate/Emcitrabine; Raltegravir/Tenofovir Fumarate/Emcitrabine; Dolutegravir/abacavir/lamivudine (for HLA-B*5701 negative patients); Elitegravir-cobicistat/Tenofovir Fumarate/Emcitrabine, Elitegravir-cobicistat/Tenofovir Alafenamide/Emcitrabine) and one protease inhibitor-based regimen (Darunavir-ritonavir/Tenofovir Fumarate/Emcitrabine).

Listed integrase inhibitor-based regimens have high efficacy, safety, and tolerability, as well as low drug interactions for Raltegravir/Tenofovir Fumarate/Emtricitabine.

Although not as well tolerated, listed protease inhibitor regimen (Darunavir-ritonavir/Tenofovir Fumarate/Emcitrabine) is recommended for patients who are suspected will be relatively incompliant or patients with NRTI resistance, this is because of the high genetic barrier to resistance that protease inhibitors confer. Nevertheless, because it is somewhat lower efficacy, this regimen should be avoided in individuals with CD4 count less than 200 or HIV RNA greater than 100000).

Consideration should be taken to make treatment as comfortable as possible for the patient. Listed once a day regimens include Dolutegravir/abacavir/lamivudine and Elvitegravir-Cobicistat/Tenofovir Fumarate/Emtricitabine.

Other important considerations to take when starting HIV antiretroviral therapy:

  • In patients with CKD Elvitegravir-cobicistat/Tenofovir Fumarate/Emtricitabine (CrCl greater than 70), and Elvitegravir-cobicistat/Tenofovir Alafenamide/Emtricitabine (CrCl greater than 30) should be avoided.
  • In osteoporotic patients, regimens containing Tenofovir Fumarate should be avoided. Dolutegravir/Abacavir/Lamivudine is a good regimen option for these patients.
  • For patients with HIV dementia and psychiatric illness, as well as patients on methadone, Efavirenz should be avoided.
  • Dolutegravir is to be avoided on high cardiac risk patients.
  • Dolutegravir, Efavirenz, Elvitegravir/cobicistat and protease inhibitors may cause or worsen dyslipidemias.

Pearls and Other Issues

Pre-exposure prophylaxis has been introduced in those groups who are at substantial risk of acquiring AIDS (e.g., MSM). It is an effective preventive tool for these groups, and it protects them from acquiring AIDS.

Enhancing Healthcare Team Outcomes

An evidence-based approach to preexposure HIV prophylaxis

More evidence has accumulated that pre-exposure HIV prophylaxis may be a better and more effective way to treat patients at high risk for HIV. Healthcare workers should be aware of this regimen since it is cheaper, simpler and safer than the traditional HAART regimen. Once preexposure prophylaxis is initiated, the goal is to ensure compliance, side effects of the medications and educate the patient on lowering of high-risk behaviors. While short-term studies indicate that pre-exposure HIV prophylaxis does work, more long-term studies are needed to determine if this also results in a lowering of HIV cases and slows down the HIV epidemic. [7][8]

 


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Acquired Immune Deficiency Syndrome (AIDS) Antiretroviral Therapy - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following is NOT an initial treatment recommended for a newly diagnosed, drug naive adult patient with a CD4 count of less than 350 cells/microL?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which antiretroviral is NOT in Atripla?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 35-year-old female presents with weight loss, night sweats, and subjective fevers. During a full workup, she is found to be HIV positive, and her CD4 count is 32. She is started on appropriate prophylactic medication. After performing genetic testing, highly active antiretroviral therapy (HAART), including tenofovir disoproxil fumarate, is recommended. Which of the following should be considered before starting HAART in this patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 48-year-old female with a history of HIV/AIDS is not taking any antiretroviral therapy, and her CD4 count was 148 a month ago. She was admitted to the hospital for fevers and abdominal pain. On admission, she was found to be tachycardic, hypotensive, and diaphoretic, and her lactate level was elevated. After appropriate fluid resuscitation, she is not responding well. It is decided to admit her to the intensive care unit (ICU). A full evaluation shows that she has sepsis from a urinary tract source of infection. The patient is started on broad-spectrum antibiotics. During a conversation with the patient at the time of admission, she requested to be started on highly active antiretroviral therapy (HAART), as she "now understands the importance of it." What is the best next step in management?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 45-year-old female with a past medical history of diabetes mellitus, hypertension, hyperparathyroidism, vitamin D deficiency, and osteoporosis presents for initiation of highly active antiretroviral therapy (HAART). A workup done at her last office visit showed that her CD4 count is 187 and her viral load is 50 million. What is the best initial treatment regimen?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 45-year-old female has a past medical history of diabetes mellitus, hypertension, chronic kidney disease IIIa, and coronary artery disease with a myocardial infarction 3 years ago. She presents for initiation of highly active antiretroviral therapy (HAART). A workup done at her last office visit showed that her CD4 count is 187, and her viral load is 50 million. What is the best initial treatment regimen?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the best initial treatment regimen for a patient with a new diagnosis of HIV/AIDS?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Acquired Immune Deficiency Syndrome (AIDS) Antiretroviral Therapy - References

References

Mehraeen E,Safdari R,SeyedAlinaghi S,Mohammadzadeh N, Exploring and prioritization of mobile-based self-management strategies for HIV care. Infectious disorders drug targets. 2018 Oct 22     [PubMed]
Finocchio T,Coolidge W,Johnson T, The ART of Antiretroviral Therapy in Critically Ill Patients With HIV. Journal of intensive care medicine. 2018 Oct 11     [PubMed]
Casper C,Crane H,Menon M,Money D, HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health null. 2017 Nov 3     [PubMed]
Monteiro S,Brigeiro M,Mora C,Vilella W,Parker R, A review of HIV testing strategies among MSM (2005-2015): Changes and continuities due to the biomedicalization of responses to AIDS. Global public health. 2018 Nov 15     [PubMed]
Pintye J,Singa B,Wanyonyi K,Itindi J,Kinuthia J,Langat A,Nganga L,Katana A,Baeten JM,McGrath CJ,John-Stewart G, Preexposure Prophylaxis for Human Immunodeficiency Virus (HIV) Prevention Among HIV-uninfected Pregnant Women: Estimated Coverage Using Risk-based Versus Regional Prevalence Approaches. Sexually transmitted diseases. 2018 Dec     [PubMed]
Fernando D, HIV Preexposure Prophylaxis. American journal of public health. 2018 Dec     [PubMed]
Capriotti T, HIV/AIDS: An Update for Home Healthcare Clinicians. Home healthcare now. 2018 Nov/Dec     [PubMed]
Myers JE,Edelstein ZR,Daskalakis DC,Gandhi AD,Misra K,Rivera AV,Salcuni PM,Scanlin K,Udeagu CC,Braunstein SL, Preexposure Prophylaxis Monitoring in New York City: A Public Health Approach. American journal of public health. 2018 Nov     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pediatric. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pediatric, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pediatric, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pediatric. When it is time for the Pediatric board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pediatric.